@reggie green @OnceUponaTime @IvanRus @valeri @Deamon22
Good News-
I emailed Professor Tzounopoulos this morning and inquired about the status of RL-81. In response he sent me the following links and attached bulletin. It appears Professor Tzounopoulos now has the funding he needed from the US Department of Defense to continue the preclinical study of RL-81 as well as another ion channel called HCN. In a separate project Professor Tzounopoulos has formed an interdisciplinary research team to study the heterogeneity of chronic tinnitus.
https://inside.upmc.com/pitt-researchers-grant-tinnitus/
http://phrc.pitt.edu/people/thanos-tzounopoulos
From INSIDE LIFE CHANGING MEDICINE
November 12, 2018
- The University of Pittsburgh (The Pittsburgh School of Medicine and Dietrich School of Arts and Science) was awarded a $2Million grant from the US Department of Defense to continue their effort to develop a new treatment for tinnitus.
- In previous work, also supported by the DoD, Professor Tzoulopoulos and Professor Peter Wipf redesigned retigabine. The new compound was known as RL-81.
- RL-81 will now undergo further animal and lab testing with the aim of gathering preclinical data before human testing is initiated.
- In the second part of the newly funded project, the researchers will also look at the role of another kind of ion channel, called HCN, in the prevention of tinnitus.
From OTOLARYNGOLOGY RESEARCH UPDATE
Fall 2018
- Professor Tzounopoulos has assembled a team of multidisciplinary researchers to investigate new models of care for tinnitus. They desire to use a new method of classification of tinnitus using precision medicine. This will help understand the heterogeneity of individuals experiencing tinnitus and what members of each subgroup have in common.
- Professor Tzounopoulos has also identified the role of free zinc in the auditory cortex for adjusting the responsiveness of the brain to sound.
Based on this information, I too will be donating to Tinnitus Research at University of Pittsburgh!
TC